Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04570332
Title BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203)
Acronym SPOTLIGHT203
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Highlight Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA | ESP

Facility Status City State Zip Country Details
Centre Hospitalier Universitaire de Bordeaux Bordeaux France Details
Centre Hospitalier Universitaire de Grenoble Grenoble France Details
Hopital Lyon Sud Lyon France Details
Centre Hospitalier Universitaire de Nantes Nantes France Details
Centre Hospitalier Universitaire de Nice Nice France Details
Hôpital Ambroise-Paré Paris France Details
Institut Gustave Roussy Paris France Details
H. Universitari Germans Trias i Pujol Badalona Barcelona Spain Details
Hospital Universitario de Canarias La Laguna Tenerife Spain Details
H. Universitari Quirón Dexeus Barcelona Spain Details
Hospital Clinic de Barcelona Barcelona Spain Details
Hospital Clara Campal - HM Sanchinarro Madrid Spain Details
Hospital General Universitario Gregorio Marañón Madrid Spain Details
Hospital Universitario 12 de Octubre Madrid Spain Details
MD Anderson Cancer Center Madrid Spain Details
Hospital Clínico Universitario Virgen de la Arrixaca Murcia Spain Details
Clínica Universidad de Navarra Pamplona Spain Details
Hospital Universitario Virgen Macarena Sevilla Spain Details
H. General Universitario de Valencia Valencia Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field